In the run up to the Developability of Biopharmaceuticals conference (4 -6 December 2012, Boston), Nick Turner of Hanson Wade recently interviewed one of the speakers, Bernhardt Trout from MIT. Bernhardt is the Director of the Novartis-MIT Center for Continuous Manufacturing and focuses on molecular engineering. He is hugely knowledgeable on the industry and his thoughts on the future of the field carry enormous weight and make for an insightful read. Click here to read.
The transcript of the whole interview is available to download on the website but specific highlights include:
- Bernhardt’s views on the recent breakthroughs that have progressed developability the most in pharmaceutical industry
- His opinions on the value that can be extracted from carrying out a developability assessment in early drug development
- His excitement on the future of developability in drug development